Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

  • Technology appraisal guidance
  • TA886
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence